Abstract: The invention relates to pharmaceutical compositions for the treatment or prevention of lesions of gastrointestinal mucous membranes and having secretion inhibiting, cytoprotective activities. The compositions contain in a biologically effective quantity a triazole-group-substituted quinoline derivative of general formula (I)R.sup.1 stands for a 1-triazolyl-group in position 2 or 4 ora 3-triazolyl-thio ora 5-/C.sub.1-4 -alkyl/-3-triazolyl-thio-group,R.sup.2 stands for a hydrogen atom in position 3 or optionally in position 2, or for a C.sub.1-4 -alkyl-group,R.sup.3 stands for a hydrogen atom or for a C.sub.1-4 -alkyl-group,X stands for a hydrogen or halogen-atom or for a C.sub.1-4 -alkyl-group or its salts. The invention includes processes for the preparation of the above compositions, and methods for treatment of patients in need of such treatment by administering the substance or the composition. The prefered substance of formula (IV) is also subject of the invention.

Abstract: The invention relates to benzopyran compounds of formula (I) possessing pharmacological activity, as well as to pharmaceutical compositions containing the compounds of formula (I) and processes for the preparation thereof.

Abstract: The invention relates to new triazolyl quinoline derivatives and acid addition salts thereof whereinR.sup.1 stands for hydrogen, methyl, trihalogenomethyl or carboxy;R.sup.2 is hydrogen, halogen, C.sub.1-4 alkyl, hydroxy, C.sub.1-4 alkoxy, phenoxy, amino, acetamino, C.sub.1-4 dialkylamino, acetyl, benzoyl, methylthio, carboxy, cyano, ethoxycarbonyl, nitro or trihalogenomethyl;R.sup.3 represents hydrogen, C.sub.1-4 alkyl or C.sub.1-4 alkoxy;R.sup.4 stands for hydrogen, methyl or ethyl andX stands for a valency bond or --S--.The new compounds of the general Formula (I) ##STR1## possess valuable analgesic, antiphlogistic and fungicidal effect and can be used both in therapy and agriculture.

Abstract: The invention refers to new diamines of the Formula I ##STR1## wherein R stands for ##STR2## or --NH--COA.sup.1 --R.sup.4 or ##STR3## wherein A stands for C.sub.1-5 alkylene which can be substituted by hydroxyl,X stands for a single or double bond,R.sup.2 stands for aryl or heteroaryl optionally substituted by halogen, C.sub.1-4 alkoxy or acylamino,R.sup.3 stands for hydrogen or C.sub.1-4 alkyl,A.sup.1 stands for a single bond or C.sub.1-5 alkyl optionally substituted by hydroxyl or thioalkylene or oxyalkylene,R.sup.4 stands for a 5- or 6- membered aromatic or heteroaromatic ring which can be substituted by one or more hydroxyl, C.sub.1-4 alkyl and/or C.sub.1-4 alkoxy and/or halogen or methylenedioxy and the alkyl group can be unsaturated as well,Q stands for a 6-membered ring which can be partially hydrogenated, andR.sup.1 stands for C.sub.1-4 alkyl.The new compounds are antiarrhythmic agents.

Abstract: The invention refers to new diamines of the Formula I ##STR1## wherein R stands for ##STR2## wherein A stands for C.sub.1-5 alkylene which can be substituted by hydroxyl,X stands for a single or double bond,R.sup.2 stands for aryl or heteroaryl optionally substituted by halogen, C.sub.1-4 alkoxy or acylamino,R.sup.3 stands for hydrogen or C.sub.1-4 alkyl,A.sup.1 stands for a single bond or C.sub.1-5 alkyl optionally substituted by hydroxyl or thioalkylene or oxyalkylene,R.sup.4 stands for a 5- or 6- membered aromatic or heteroaromatic ring which can be substituted by one or more hydroxyl, C.sub.1-4 alkyl and/or C.sub.1-4 alkoxy and/or halogen or methylenedioxy and the alkyl group can be unsaturated as well,Q stands for a 6-membered ring which can be partially hydrogenated, andR.sup.1 stands for C.sub.1-4 alkyl.The new compounds are antiarrhythmic agents.

Abstract: The invention refers to new diamines of the Formula I ##STR1## wherein stands for ##STR2## wherein A stands for C.sub.1-5 alkylene which can be substituted by hydroxyl,X stands for a single or double bond,R.sup.2 stands for aryl or heteroaryl optionally substituted by halogen, C.sub.1-4 alkoxy or acylamino,R.sup.3 stands for hydrogen or C.sub.1-4 alkyl,A.sup.1 stands for a single bond or C.sub.1-5 alkyl optionally substituted by hydroxyl or thioalkylene or oxyalkylene,R.sup.4 stands for a 5- or 6- membered aromatic or heteroaromatic ring which can be substituted by one or more hydroxyl, C.sub.1-4 alkyl and/or C.sub.1-4 alkoxy and/or halogen or methylenedioxy and the alkyl group can be unsaturated as well,Q stands for a 6-membered ring which can be partially hydrogenated, andR.sup.1 stands for C.sub.1-4 alkyl.The new compounds are antiarrhythmic agents.

Abstract: Compounds are disclosed of the formula (I) ##STR1## wherein A.sup.1 is a valence bond or a C.sub.1 to C.sub.5 straight or branched chain alkylene group unsubstituted or substituted by hydroxy or aminocarbonyl;B is a valence bond or a double bond;R.sup.3 is hydrogen or C.sub.1 to C.sub.4 alkyl;R.sup.2 is a phenyl or phenoxy group unsubstituted or substituted by one or two C.sub.1 to C.sub.4 alkyl groups, C.sub.1 to C.sub.4 alkoxy groups, or halo substituents; or R.sup.2 is an amino group, a diphenylmethyl group, or an R.sup.4 --NH--CO-- group in whichR.sup.4 is 2,6-dimethyl-phenyl; or a pharmaceutically acceptable acid addition salt thereof. The compounds possess anti-arrhythmic activity and exert little or no hypotensive side effects.

Abstract: The invention relates to new anti-arrhythmic compounds of the formula (I) ##STR1## wherein A is C1 to C5 alkylene which can be substituted by hydroxyl;X is a single or a double bond; andQ is a 6-membered carbocyclic moiety fused to each of the adjacent carbonyl carbon atoms, and which is either fully hydrogenated, partially hydrogenated, or aromatic, or a pharmaceutically acceptable acid addition salt thereof.